User profiles for Natalie Groves

Natalie Groves

Queensland Brain Institute
Verified email at uq.edu.au
Cited by 722

[HTML][HTML] Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant

…, S Thelwall, J Stowe, E Tessier, N Groves… - … England Journal of …, 2021 - Mass Medical Soc
Background The B.1.617.2 (delta) variant of the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), has …

[HTML][HTML] Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant

…, S Thelwall, J Stowe, E Tessier, N Groves… - The New England …, 2021 - ncbi.nlm.nih.gov
Background The B. 1.617. 2 (delta) variant of the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), has …

[HTML][HTML] Assessing transmissibility of SARS-CoV-2 lineage B. 1.1. 7 in England

…, R Myers, V Hill, DK Jackson, K Gaythorpe, N Groves… - Nature, 2021 - nature.com
The SARS-CoV-2 lineage B.1.1.7, designated variant of concern (VOC) 202012/01 by Public
Health England 1 , was first identified in the UK in late summer to early autumn 2020 2 . …

[HTML][HTML] Duration of protection against mild and severe disease by Covid-19 vaccines

…, E Gallagher, S Thelwall, N Groves… - … England Journal of …, 2022 - Mass Medical Soc
Background Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
the virus that causes coronavirus disease 2019 (Covid-19), have been used since …

[HTML][HTML] Covid-19 vaccine effectiveness against the Omicron (B. 1.1. 529) variant

…, E Gallagher, C Gower, M Kall, N Groves… - … England Journal of …, 2022 - Mass Medical Soc
Background A rapid increase in coronavirus disease 2019 (Covid-19) cases due to the
omicron (B.1.1.529) variant of severe acute respiratory syndrome coronavirus 2 in highly …

Transmission of SARS-CoV-2 Lineage B. 1.1. 7 in England: Insights from linking epidemiological and genetic data

…, R Myers, V Hill, DK Jackson, K Gaythorpe, N Groves… - MedRxiv, 2021 - medrxiv.org
The SARS-CoV-2 lineage B.1.1.7, now designated Variant of Concern 202012/01 (VOC) by
Public Health England, originated in the UK in late Summer to early Autumn 2020. We …

Effectiveness of COVID-19 vaccines against the Omicron (B. 1.1. 529) variant of concern

…, T Rickeard, E Gallagher, C Gower, M Kall, N Groves… - MedRxiv, 2021 - medrxiv.org
Background A rapid increase in cases due to the SARS-CoV-2 Omicron (B.1.1.529) variant
in highly vaccinated populations has raised concerns about the effectiveness of current …

COVID-19 vaccine effectiveness against the omicron (BA. 2) variant in England

…, R Sachdeva, E Gallagher, N Groves… - The Lancet Infectious …, 2022 - thelancet.com
The omicron (B. 1.1. 529) variant, first detected in the UK on Nov 27, 2021, rapidly became
the dominant strain, due in part to reduced vaccine effectiveness. 1 An increase in sequenced …

[HTML][HTML] Household transmission of COVID-19 cases associated with SARS-CoV-2 delta variant (B. 1.617. 2): national case-control study

…, D Chudasama, T Lamagni, N Groves… - The Lancet Regional …, 2022 - thelancet.com
Background The SARS-CoV-2 Delta variant (B.1.617.2), first detected in India, has rapidly
become the dominant variant in England. Early reports suggest this variant has an increased …

The origins and molecular evolution of SARS-CoV-2 lineage B. 1.1. 7 in the UK

…, AM Carabelli, N Ellaby, E Gallagher, N Groves… - Virus …, 2022 - academic.oup.com
The first SARS-CoV-2 variant of concern (VOC) to be designated was lineage B.1.1.7, later
labelled by the World Health Organization as Alpha. Originating in early autumn but …